CanCerFebruary 2, 2006
The cancer drug Herceptin®
has been used
successfully for several years in treating
women with a particularly virulent form
of breast cancer that has spread to other
organs. But could it work as effectively in
earlier-stage disease to...
More
CanCerFebruary 2, 2006
The cancer drug Herceptin®
has been used
successfully for several years in treating
women with a particularly virulent form
of breast cancer that has spread to other
organs. But could it work as effectively in
earlier-stage disease to prevent metastasis
(spread of cancer to other organs)? Medical
researchers set out to answer this question in
clinical trials involving of 3,351 women, and
the results turned out to be stunning.
The trials were sponsored by the National
Cancer Institute and conducted by a network
of researchers led by National Surgical
Adjuvant Breast and Bowel Project and the
North Central Cancer Treatment Group, in
collaboration with the Cancer and Leukemia
Group B, the Eastern Cooperative Oncology
Group and the Southwest Oncology Group.
Genentech Inc., which manufactures
trastuzumab under the brand Herceptin,
provided the drug. More than 500 testing
sites throughout the U.S. and Canada were
involved. Results were published in the New
England Jour
Less
